Wild-type (senile) amyloidosis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 175: Line 175:


{|
{|
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Causes}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Clinical Features}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Therapy}}
|-
|-
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}}
Line 191: Line 184:
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Therapy}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Therapy}}
|-
|-
| rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Polyneuropathy'''''
| rowspan="7" |'''''Polyneuropathy'''''
|
|
|
|
|
|
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[POEMS syndrome]] (Demyelinating)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[POEMS syndrome]] (Demyelinating)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 800: Line 800:
* Supporting findings can include elevation of inflammatory markers ([[C-reactive protein (CRP)|C-reactive protein]], [[Erythrocyte sedimentation rate|ESR]], [[white blood cell count]]), and evidence of pericardial inflammation on imaging([[Computed tomography|CT scan]] and [[cardiac MRI]]).
* Supporting findings can include elevation of inflammatory markers ([[C-reactive protein (CRP)|C-reactive protein]], [[Erythrocyte sedimentation rate|ESR]], [[white blood cell count]]), and evidence of pericardial inflammation on imaging([[Computed tomography|CT scan]] and [[cardiac MRI]]).
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}}
|-
| rowspan="4" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Plasma Cell Dyscrasias'''''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multiple myeloma]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*[[Malignant]] transformation of [[plasma cells]]
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diffuse [[bone]] pain and [[tenderness]] with [[osteolytic]] lesions
*[[Renal failure]]
*[[Hypercalcemia]]
*[[Anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Anemia]]
*[[Thrombocytopenia]]
*[[Leukopenia]]
* Decreased albumin (reversed albumin:globulin ratio)
* Increased serum creatinine, urea
* Hypercalcemia
* Elevated ESR
* Normal-low alkaline phosphatase
* RBC rouleaux formation
* Bence-Jones proteins in urine
| style="padding: 5px 5px; background: #F5F5F5;" |
* Clonal plasma cells on bone marrow exam greater than equal to 10%
AND
* Any one of the following:
** Evidence of end-organ damage
** Hypercalcemia (>11 mg/dl)
** Renal insufficiency
** Anemia (Hb < 10 mg/dl)
** Bone lesions
** Greater than 1 lesions on MRI
| style="padding: 5px 5px; background: #F5F5F5;" |
*Induction [[chemotherapy]] with [[bortezomib]], [[lenalidomide]], and [[dexamethasone]]
*[[Bisphosphonates]]
*[[RANKL|RANK ligand]] inhibitors ([[denosumab]])
*[[Autologous bone marrow transplantation|Autologous stem cell transplantation]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Monoclonal gammopathy of undetermined significance]] ([[MGUS]])'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Asymptomatic]]
*
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Serum]] [[M protein]] of <3 g/L
* Fewer than 10% [[plasma cells]] in the [[bone marrow]]
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
| style="padding: 5px 5px; background: #F5F5F5;" |
* Serum M protein (IgG or IgA) <3g/dl
AND
* Clonal bone marrow plasma cells < 10%
AND
* No end-organ damage
| style="padding: 5px 5px; background: #F5F5F5;" |
* Observation
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multiple Myeloma|Asymptomatic Plasma Cell Myeloma]]'''
[[Multiple Myeloma|('''Smoldering''' and '''Indolent plasma cell myeloma''')]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*[[Malignant]] transformation of [[plasma cells]]
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Asymptomatic]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Serum]] [[M protein]] of  greater than equal to 3 g/L
* Greater than 10% [[plasma cells]] in the [[bone marrow]]
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
| style="padding: 5px 5px; background: #F5F5F5;" |
* Serum M protein (IgG or IgA greater than equal to 3 g/dl
OR
* Urinary M protein greater than equal to 500 mg/24 h
AND/OR
* Clonal bone marrow plasma cells 10-60%
AND
* No end-organ damage
| style="padding: 5px 5px; background: #F5F5F5;" |
* Observation
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasmacytoma]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*[[Malignant]] transformation of [[plasma cells]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* Solitary bone [[plasmacytoma]] ([[bone]])
* Extramedullary [[plasmacytoma]] ([[Soft tissue|soft tissues]])
* Clinical manifestations related to [[tumor]] mass and compression [[symptoms]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* On biopsy:
** Solitary infiltrate of clonal plasma cells in bone (SBP) or soft tissue (EMP).
** No evidence of infiltration by clonal plasma cells.
* Negative skeletal survey plus MRI/CT spine and pelvis except for the solitary lesion.
* Lack of hypercalcemia, renal insuffieciency, anemia, multiple bone lesions which would suggest MM
| style="padding: 5px 5px; background: #F5F5F5;" |
* Diagnosis of exclusion
| style="padding: 5px 5px; background: #F5F5F5;" |
* Radiotherapy
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Skin Changes
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Scurvy]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Vitamin C]] deficiency
*[[Malabsorption]]
*[[Hemodialysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Gum disease]] such as gum [[bleeding]]
*Loose [[teeth]]
*Easy [[bruising]]
*Impaired [[immune]] response
*Impaired [[wound]] healing
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Vitamin C]] supplementation
*Citrus fruits
|}
|}



Revision as of 20:48, 19 December 2019

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis differential diagnosis

CDC on Wild-type (senile) amyloidosis differential diagnosis

Wild-type (senile) amyloidosis differential diagnosis in the news

Blogs on Wild-type (senile) amyloidosis differential diagnosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

Differentiating Wild-type (Senile) Amyloidosis from other Diseases

Differentials Based on Cardiac Involvement (Heart Failure)

Wild-type (senile) amyloidosis should be differentiated from other causes of heart failure:

Differential Diagnosis History and Symptoms Physical Examination Laboratory Findings Imaging Findings
Cardiac amyloidosis
  • Elevated jugular pressure

Periorbital purpura: Often occurs with sneezing, coughing or with minor trauma. Indicates capillary involvement of AL type amyloidosis.

  • Macroglossia
  • Abnormal phonation
  • Hepatomegaly
  • Ascites may be present in the setting of heart failure
  • Valvular involvement murmurs of mitral and tricuspid regurgitation (systolic).


  • Normocytic mormochromic anemia
  • Serum free-light-chain assay positive
  • Increased BNP, ANP and β2 microglobulin
  • Voltage-to-mass ratio is more sensitive than EKG, 2D Echo and nuclear scanning alone
Cardiac sarcoidosis
  • Asymptomatic conduction abnormalities
  • Chest pain
  • Congestive heart failure symptoms:
    • Fatigue
    • Syncope
    • Dyspnea
    • Chest pain.
    • Irregular heartbeats
    • Palpitations
    • edema
  • Ventricular tachyarrhythmia
  • Heart block
  • Valvular regurgitation
  • Pericardial effusion
  • Constrictive pericarditis or temponade
  • Serum markers that have been reported as markers of sarcoidosis in general are:
    • Serum amyloid A (SAA)
    • Soluble interleukin-2 receptor (sIL-2R)
    • Lysozyme
    • Angiotensin-converting enzyme (ACE)
    • Gycoprotein KL-6
    • Hypercalcemia
    • Hypercalciuria
    • (noncaseating granulomas secrete 1,25 vitamin D)
  • Radionuclide examinations
    • Thallium‐201 scintigraphy
    • Gallium‐67 scintigraphy
    • Positron emission tomography
  • Magnetic resonance imaging
  • Samples of myocardium with sarcoidosis shows the following:
  • Non‐caseating, multinucleated giant cell granuloma in the subendocardium
  • Trichrome stain can show a dense band of collagen fibers, encasing aggregate of granulomas and inflammatory cells
ST Segment Elevation Myocardial Infarction
  • Chest pain with possible radiation to left arm and lower jaw
  • Squeezing, crushing chest pain
  • Sweating
  • Nausea and vomiting
  • Anxious patient in pain with diaphoresis
  • Signs of heart failure may be present
  • Arrhythmia
  • ST elevation, new left bundle branch block, and Q wave on EKG
  • Elevated cardiac biomarkers
  • Either complete or subtotal occlusion of an epicardial coronary artery on coronary angiography
  • Confluent hyperenhancement extending from the endocardium
Non ST Elevation Myocardial Infarction
  • Crushing, left-sided substernal chest pain or pressure that radiates to the neck or left arm
  • Same as ST-elevation MI
  • ST-segment depression or T-wave inversion on EKG
  • Elevated cardiac biomarkers
Pericarditis
  • Chest pain relieved by sitting up and leaning forward and worsened by lying down
  • Fever, anxiety, difficulty breathing
  • Pericardial friction rub
  • Signs of cardiac tamponade may be present
  • PR segment depression and electrical alternans on EKG
  • A flask-shaped, enlarged cardiac silhouette on CXR
  • Pericardial thickness of more than 4 mm on MRI
  • Pericardial effusion and cardiac chamber indentation or collapse on echo when cardiac tamponade is present
Alcoholic Cardiomyopathy
  • History of alcohol abuse
  • Fatigue, weakness, anorexia, palpitations, and shortness of breath on activity
  • Leg swelling and pedal edema
  • Signs of heart failure such as presence of S3 and S4 heart sounds, pedal edema, and jugular venous distension
  • Signs of alcoholic liver disease may be present
  • Elevated MCV and MCHC on CBC
  • Elevated LDH, AST, ALT, creatine kinase, gammaglutamyl transpeptidase, malic dehydrogenase, and alpha-hydroxybutyric dehydrogenase
  • Q waves and non specific ST and T wave changes on EKG
  • Cardiomegaly, pulmonary congestion, and pleural effusions on CXR
  • Left ventricular dilatation on echo


Differentials Based on Presentation As a Multi-Organ System Dysfunction Disorder


Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Polyneuropathy
POEMS syndrome (Demyelinating)
Metabolic Syndrome (Axonal pathology)
Vitamin Deficiencies (Axonal Pathology)
Guillain-Barre Syndrome (Demyelinating)
  • Delayed F waves
  • Clinical diagnostic criteria (progressive weakness of more than two limbs, areflexia, and progression for no more than four weeks)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing)
  • EFNS/PNS criteria
  • Koski criteria
Multifocal Motor Neuropathy
  • Progressive, asymmetric, distal and upper limb predominant weakness
  • No significant sensory abnormalities
  • Areflexia
  • Clinical criteria (EFNS/PNS):
    • Slowly progressive or step-wise progressive, focal, asymmetric limb weakness; i.e., motor involvement in the motor nerve distribution of at least two nerves for > 1 month.
    • No objective sensory abnormalities except for minor vibration sense abnormalities in the lower limbs
Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) Malaria
Kala-azar
Infective Hepatitis
Chronic Myelogenous Leukemia (CML)
Lymphoma
Primary (AL) Amyloidosis
  • Typical green birefringence under polarized light after Congo red staining (appears in red under normal light)
  • Congo red staining
  • Melphalan-prednisone/dexamethasone
  • Dexamethasone plus Cyclophosphamide-thalidomide
  • Stem cell transplantation
Gaucher's Disease
Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Cardiac Failure Cardiac amyloidosis (AL and ATTRwt)
  • Monoclonal plasma cell proliferation
  • Extracellular amyloid fibril deposition
  • Fatigue
  • Dyspnea
  • Dizziness
  • Orthopnea
  • Peripheral edema
  • Weight loss due to cardiac cachexia
  • Ascites
  • Syncope on exertion
  • Transthyretin (ATTRwt) associated more common in African-Americans during sixth to seventh decade of life
  • Normocytic mormochromic anemia
  • Serum free-light-chain assay positive
  • Increased BNP, ANP and β2 microglobulin
  • Voltage-to-mass ratio is more sensitive than EKG, 2D Echo and nuclear scanning alone
  • Biopsy:
  • Diffuse deposition of amorphous hyaline material (nodular pattern - 8 to15 nm in diameter), in mesangium (weakly staining with periodic acid-Schiff (PAS)


  • Supportive care
  • Tafamidis
  • Melphalan-prednisone/dexamethasone
  • Dexamethasone plus Cyclophosphamide-thalidomide
Cardiac sarcoidosis
  • The causes are not fully known.
  • Over-reaction of the immune system after exposure to an infectious agent (bacteria or viruses), chemical, or allergen.
  • Excessive inflammation and the clustering of white blood cells.
  • Asymptomatic conduction abnormalities
  • Chest pain
  • Congestive heart failure symptoms:
    • Fatigue
    • Syncope
    • Dyspnea
    • Chest pain.
    • Irregular heartbeats
    • Palpitations
    • edema

Serum markers that have been reported as markers of sarcoidosis in general are:

  • Serum amyloid A (SAA)
  • Soluble interleukin-2 receptor (sIL-2R)
  • Lysozyme
  • Angiotensin-converting enzyme (ACE)
  • Gycoprotein KL-6
  • Hypercalcemia
  • Hypercalciuria
  • (noncaseating granulomas secrete 1,25 vitamin D)
  • Biopsy: samples of myocardium with sarcoidosis shows the following:
  • Non‐caseating, multinucleated giant cell granuloma in the subendocardium
  • Trichrome stain can show a dense band of collagen fibers, encasing aggregate of granulomas and inflammatory cells
  • Corticosteroid treatment
  • Antiarrhythmic treatment
  • Pacemakers and defibrillators
  • Cardiac transplantation
Hypertrophic obstructive cardiomyopathy


  • Echocardiography:
    • Left ventricular asymmetric hypertrophy
    • Parasternal long axis shows relationship of the septal hypertrophy and the outflow tract
    • Left ventricular diastolic dysfunction
    • SAM (systolic anterior motion) of the mitral leaflet
    • Mid-systolic closure of the aortic valve
    • Late peaking, high velocity flow in the outflow tract
    • Variability of obstruction with maneuvers (exercise, amyl nitrate inhalation, and post-PVC beats)
Alcoholic cardiomyopathy
  • Alcohol consumption


ST-elevation myocardial infarction
Pericarditis



References